Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A subject must meet all of the following criteria to be eligible for this study.~1. The subject and/or their parent/legal guardian are willing and able to provide signed informed consent.~2. The subject has successfully completed 28 weeks of treatment in Study 4658-US-201.~3. The subject has a parent(s) or legal guardian(s) who is able to understand and comply with all of the study procedure requirements.~Exclusion Criteria:~A subject who meets any of the following criteria will be excluded from this study.~1. The subject has a prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the subject or make it unlikely that the course of treatment or follow-up would be completed or impair the assessment of study results.

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- AVI-4658 (Eteplirsen) (Type: EXPERIMENTAL): Multiple-Dose Extension Study

Based on this trial design, predict the completion outcome and termination type (if applicable).